Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ABEO
ABEO logo

ABEO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Abeona Therapeutics Inc (ABEO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.550
1 Day change
3.80%
52 Week Range
7.540
Analysis Updated At
2026/07/02
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ABEO is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 ready to deploy. The stock has short-term bullish momentum, but the move looks extended after a sharp daily gain and there is no AI Stock Picker or SwingMax buy signal to back an aggressive entry. For an impatient buyer, this is better treated as a hold than an immediate purchase.

Technical Analysis

ABEO is in a bullish short-term trend: MACD histogram is positive and expanding, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. Price closed at 6.575, above pivot 5.922 and above R1 6.268, showing strength. However, RSI_6 at 79.764 suggests the stock is stretched after the recent 5.79% regular-session rise, so upside continuation may be less favorable for a fresh long-term entry at this level. The model-based stock trend also implies only modest follow-through over the next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bullish. The open interest put-call ratio of 0.24 is strongly call-skewed, showing traders are leaning optimistic. Call open interest (11,320) is much higher than puts (2,716), and implied volatility at 153.66 is elevated, indicating active expectations for price movement. However, today’s option volume was extremely light, so the sentiment signal is more from positioning than from strong current trading flow.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
10

Positive Catalysts

  • Recent price momentum is strong, with the stock up 5.79% in regular trading and continuing higher after hours. Technical structure remains bullish with aligned moving averages and positive MACD expansion. Options positioning is heavily call-skewed, which supports a constructive near-term sentiment. The only news catalyst provided was a small restricted-share grant to new employees, which is mildly supportive as a talent-retention move but not a major growth catalyst.

Neutral/Negative Catalysts

  • The stock appears extended in the short term, with RSI near overbought levels and a likely weak next-day return based on the candlestick-pattern study. There is no AI Stock Picker or SwingMax entry signal today. Hedge funds and insiders are both neutral, so there is no strong smart-money confirmation. No meaningful analyst upgrade or price-target momentum was provided, and there is no financial quarter data to confirm fundamental acceleration.

Financial Performance

No usable latest-quarter financial snapshot was provided because of an error, so there is no confirmed revenue, earnings, or margin update to assess. The latest quarter season cannot be identified from the supplied data. Because of that, there is no evidence here to support a fundamental long-term buy case from recent financial performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price-target trend data was provided, so there is no clear evidence of a recent Wall Street upgrade cycle or target increase. Based on the available information, Wall Street sentiment appears neutral-to-mixed rather than strongly bullish. Pros: improving technical momentum and bullish options skew. Cons: no analyst catalyst, no strong institutional or insider buying, and no fundamental update to justify chasing the move.

Wall Street analysts forecast ABEO stock price to rise
4 Analyst Rating
Wall Street analysts forecast ABEO stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.310
sliders
Low
20
Averages
25.17
High
28
Current: 6.310
sliders
Low
20
Averages
25.17
High
28
Alliance Global
Buy
downgrade
$20
AI Analysis
2026-03-17
Reason
Alliance Global
Price Target
$20
AI Analysis
2026-03-17
downgrade
Buy
Reason
Alliance Global lowered the firm's price target on Abeona Therapeutics to $20 from $27.50 and keeps a Buy rating on the shares following FY25 results. Alliance Global told investors in a research note that the company's earnings conference call focus included Zevaskyn's early launch progression, particularly the scale-up of Abeona Therapeutics' Qualified Treatment Center network to progress patient treatment. The firm noted that the price target cut accounts for its adjusted launch expectations of a more conservative launch trajectory.
Stifel
Stephen Willey
Buy
downgrade
$20 -> $19
2025-11-12
Reason
Stifel
Stephen Willey
Price Target
$20 -> $19
2025-11-12
downgrade
Buy
Reason
Stifel analyst Stephen Willey lowered the firm's price target on Abeona Therapeutics to $19 from $20 and keeps a Buy rating on the shares. Management's temporary pause on patient biopsy collection sets back the commercial launch by about three months and decreases confidence in the firm's now-lower Q4 estimate as a result of the temporal uncertainty associated with the timing of revenue recognition, the analyst tells investors in a research note. The firm added that increasing patient demand strengthens its confidence in FY26 and beyond, and believes the set-up here offers an attractive risk/reward.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ABEO
Unlock Now

People Also Watch